Literature DB >> 7460485

Debrisoquine hydroxylation capacity: problems of assessment in two populations.

T Inaba, S V Otton, W Kalow.   

Abstract

Following the investigation of debrisoquine (D) metabolism to 4-hydroxydebrisoquine (4OHD) in two populations, problems with the current practice of assessing this capacity by urinary D:4OHD ratios presented themselves. The distributions of both components of this ratio, when examined separately, clearly displayed interethnic differences. The mean 0- to 8-hr recovery of 4OHD in the Caucasian group was 15.5 +/- 1.1% (SE) of a 20-mg dose and 8.0 +/- 1.5% in the Oriental group. The corresponding values for unchanged D excretion were 33.0 +/- 4.1% in Orientals and 18.2 +/- 2.3% in Caucasians, a difference that is overlooked when D:4OHD ratios alone are examined. Although D and 4OHD excretion rates were equally variable, they correlated poorly; that is, they tended to vary independently of each other. This finding, in conjunction with the two separate ethnic differences, indicates that the ratio D:4OHD does not solely reflect an individual's capacity towards D 4-hydroxylation, and that equating these is unwarranted. This limitation does not necessarily invalidate judicious use of the ratio at the edges of the distribution curve, but it does call for additional investigations into the means to assess D metabolizing capacity in most subjects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7460485     DOI: 10.1038/clpt.1981.35

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.

Authors:  P R Jackson; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

2.  Diurnal effects on debrisoquine hydroxylation phenotyping.

Authors:  E J Lee
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.

Authors:  N K Zgheib; R F Frye; T S Tracy; M Romkes; R A Branch
Journal:  Br J Clin Pharmacol       Date:  2006-10-19       Impact factor: 4.335

4.  Statistical analysis of polymorphic drug metabolism data using the Rosin Rammler Sperling Weibull distribution.

Authors:  D B Jack
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine.

Authors:  Stefano Zamuner; Brendan M Johnson; Sabrina Pagliarusco; Paolo Fina; Michela Peroni; Monica Fiore; Laurel M Adams; Sofia A Fernandes
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

6.  Oxidative polymorphism of dextromethorphan in a Burundi population.

Authors:  F Nsabiyumva; Y Furet; E Autret; A P Jonville; M Breteau
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Desipramine pharmacokinetics in Chinese and Caucasian volunteers.

Authors:  M V Rudorfer; E A Lane; W H Chang; M D Zhang; W Z Potter
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

8.  Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.

Authors:  J O Atiba; T F Blaschke; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

9.  Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.

Authors:  M Eichelbaum; N M Woolhouse
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 10.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.